Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

92.61USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$92.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,725,096
52-wk High
$125.84
52-wk Low
$83.25

Select another date:

California insurance regulator sues AbbVie alleging Humira kickbacks

Insurance Commissioner Dave Jones on Tuesday filed a complaint on behalf of the State of California against AbbVie Inc, alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe its blockbuster drug, Humira.

UPDATE 1-California insurance regulator sues AbbVie alleging Humira kickbacks

Sept 18 Insurance Commissioner Dave Jones on Tuesday filed a complaint on behalf of the State of California against AbbVie Inc, alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe its blockbuster drug, Humira.

California insurance commissioner sues AbbVie over Humira

Sept 18 Insurance Commissioner Dave Jones on Tuesday filed a complaint on behalf of the State of California against AbbVie Inc, alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe its blockbuster drug, Humira.

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.

UPDATE 2-AbbVie cash cow Humira barely beats sales estimates, stock slides

* Stock down 5 percent in afternoon trade (Adds details from conference call, updates share movement)

AbbVie tops second-quarter estimates, sets higher earnings target

July 27 AbbVie Inc on Friday topped Wall Street estimates for second-quarter profit and raised its yearly earnings forecast, led by stronger demand for top-selling drugs Humira and Imbruvica.

UPDATE 1-Citron's Left reiterates belief AbbVie shares will fall sharply

NEW YORK, July 24 Short-seller Andrew Left's Citron Research expanded on his prediction that U.S. drugmaker AbbVie Inc's stock would fall to $60 a share, arguing that new regulations to speed biosimilar drugs to the market and reform rebates will hurt revenue from the company's top-selling drug, Humira.

Citron's Left reiterates belief AbbVie shares will fall sharply

NEW YORK, July 24 Short-seller Andrew Left's Citron Research expanded on his prediction that U.S. drugmaker AbbVie Inc's stock would fall to $60 a share, arguing that new regulations to speed biosimilar drugs to the market and reform rebates will hurt revenue from the company's top-selling drug, Humira.

AbbVie prices new endometriosis drug at $10,000 a year

NEW YORK Drugmaker AbbVie Inc priced its new endometriosis drug Orilissa at around $10,000 a year after receiving approval from U.S. regulators for the treatment on Tuesday.

AbbVie prices new endometriosis drug at $10,000 a year

NEW YORK, July 24 Drugmaker AbbVie Inc priced its new endometriosis drug Orilissa at around $10,000 a year after receiving approval from U.S. regulators for the treatment on Tuesday.

Select another date: